Clinical Trial Update: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating rituximab maintenance therapy for CD20-positive aggressive lymphoma and mantle cell lymphoma; no results are provided in this up…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: University Hospital Heidelberg | Conditions: CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma | Phase 3 | Status: UNKNOWN